ReviewAnnual review of pharmacology and toxicology2007
Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.
Review in Annual review of pharmacology and toxicology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 1 synthesis or guideline pooled it, 288 citations in OpenAlex.
- Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.European journal of clinical pharmacology · 2017Pooled it
- Milrinone relaxes pulmonary veins in guinea pigs and humans.PloS one · 2014Trial
- Article
- Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.Kidney international reports · 2026Review
- Ambrisentan attenuates cisplatin-related mitochondrial dysfunction in the heart via regulation of p53 and NF-κB signaling.Scientific reports · 2026Article
- Modulating Renal Fibrosis: The Emerging Role of Hepatocyte Growth Factor.International journal of nephrology · 2026Review
- Endothelin-1 drives COX-2 and prostaglandin EJournal of dental sciences · 2026Article
- Combined Effects of Diosmin, Hesperidin,International journal of molecular sciences · 2025Article
- Dual ETFundamental & clinical pharmacology · 2025Article
- Molecular Mechanisms of Vascular Tone in Exercising Pediatric Populations: A Comprehensive Overview on Endothelial, Antioxidative, Metabolic and Lipoprotein Signaling Molecules.International journal of molecular sciences · 2025Review
- High levels of uric acid upregulate endothelin receptors: the role of MAPK pathways in anArchives of medical science : AMS · 2025Article
- Comprehensive Insights into Mechanisms for Ventricular Remodeling in Right Heart Failure.Reviews in cardiovascular medicine · 2024Review
- The MuCAYACJC open · 2024Article
- Endothelin 3/EDNRB signaling induces thermogenic differentiation of white adipose tissue.Nature communications · 2024Article
- Novel insights into the potential applications of stem cells in pulmonary hypertension therapy.Respiratory research · 2024Review
- Coronary Artery Disease Risk Variant Dampens the Expression of CALCRL by Reducing HSF Binding to Shear Stress Responsive Enhancer in Endothelial Cells In Vitro.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link?International journal of molecular sciences · 2024Review
- Endothelin receptor B-deficient mice are protected from high-fat diet-induced metabolic syndrome.Molecular metabolism · 2024Article
- Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024Review
- Murine Cytomegalovirus Infection Induced miR-1929-3p Down-Regulation Promotes the Proliferation and Apoptosis of Vascular Smooth Muscle Cells in Mice by Targeting Endothelin A Receptor and Downstream NLRP3 Activation Pathway.Molecular biotechnology · 2023Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of actions that influence homeostatic mechanisms throughout the body. Two receptor subtypes, ET(A) and ET(B), which usually have opposing actions, mediate the actions of endothelin. ET(A) receptors function to promote vasoconstriction, growth, and inflammation, whereas ET(B) receptors produce vasodilation, increases in sodium excretion, and inhibit growth and inflammation. Potent and selective receptor antagonists have been developed and have shown promising results in the treatment of cardiovascular diseases such as pulmonary arterial hypertension, acute and chronic heart failure, hypertension, renal failure, and atherosclerosis. However, results are often contradictory and complicated because of the tissue-specific vasoconstrictor actions of ET(B) receptors and the fact that endothelin is an autocrine and paracrine factor whose activity is difficult to measure in vivo. Considerable questions remain regarding whether ET(A)-selective or nonselective ET(A)/ET(B) receptor antagonists would be useful in a range of clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.